AT1 Receptor Antagonism Is Proangiogenic in the Brain: BDNF a Novel Mediator

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen et al. · The Lancet · 2002 · 5.4K citations

Hypertension, Cardiovascular Disease, Endpoint Reduction +7

Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention

Joachim Schrader, Stephan Lüders, Anke Kulschewski et al. · Stroke · 2005 · 757 citations · Full text

The ACCESS Study

Joachim Schrader, Stephan Lüders, Anke Kulschewski et al. · Stroke · 2003 · 646 citations · Full text

Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics.

Martin Schulz, A. Schmoldt · PubMed · 2003 · 444 citations

Clinical Toxicology Laboratories, Other Xenobiotics, Pharmacotherapy +19

Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.

Bernhard Schieffer, Andreas Wirger, M Meybrunn et al. · Circulation · 1994 · 420 citations